Last reviewed 2026-04-23 · How we verify

LYN-005

LYN-005 is a gastric-resident capsule designed to deliver oral medications in a controlled, prolonged manner within the stomach.

LYN-005 is a gastric-resident capsule designed to deliver oral medications in a controlled, prolonged manner within the stomach. Used for Oral drug delivery platform for various therapeutic payloads (specific indication dependent on loaded drug).

At a glance

Mechanism of action

LYN-005 is a novel drug delivery platform technology developed by Lyndra that uses a capsule that expands and lodges in the stomach, enabling extended release of therapeutic agents over days or weeks. This approach aims to improve drug bioavailability, reduce dosing frequency, and enhance patient compliance for oral medications that would otherwise require frequent dosing or have poor absorption.

Approved indications

• Oral drug delivery platform for various therapeutic payloads (specific indication dependent on loaded drug)

Common side effects

• Gastrointestinal discomfort
• Nausea
• Abdominal pain

Key clinical trials

• A Study to Evaluate the Safety and Tolerability of Long-Acting Oral Risperidone (LYN-005) in Participants With Schizophrenia or Schizoaffective Disorder (PHASE3)
• Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005 (PHASE3)
• A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• LYN-005 CI brief — competitive landscape report
• LYN-005 updates RSS · CI watch RSS
• Lyndra Inc. portfolio CI